JPWO2021003469A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021003469A5
JPWO2021003469A5 JP2021578065A JP2021578065A JPWO2021003469A5 JP WO2021003469 A5 JPWO2021003469 A5 JP WO2021003469A5 JP 2021578065 A JP2021578065 A JP 2021578065A JP 2021578065 A JP2021578065 A JP 2021578065A JP WO2021003469 A5 JPWO2021003469 A5 JP WO2021003469A5
Authority
JP
Japan
Prior art keywords
wild
residue
type human
position corresponding
human neu2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021578065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538894A5 (https=
JP2022538894A (ja
JP7777988B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040828 external-priority patent/WO2021003469A2/en
Publication of JP2022538894A publication Critical patent/JP2022538894A/ja
Publication of JP2022538894A5 publication Critical patent/JP2022538894A5/ja
Publication of JPWO2021003469A5 publication Critical patent/JPWO2021003469A5/ja
Priority to JP2025197401A priority Critical patent/JP2026032063A/ja
Application granted granted Critical
Publication of JP7777988B2 publication Critical patent/JP7777988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021578065A 2019-07-03 2020-07-03 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 Active JP7777988B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025197401A JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870403P 2019-07-03 2019-07-03
US62/870,403 2019-07-03
US202062957011P 2020-01-03 2020-01-03
US62/957,011 2020-01-03
PCT/US2020/040828 WO2021003469A2 (en) 2019-07-03 2020-07-03 Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025197401A Division JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022538894A JP2022538894A (ja) 2022-09-06
JP2022538894A5 JP2022538894A5 (https=) 2023-07-10
JPWO2021003469A5 true JPWO2021003469A5 (https=) 2023-07-10
JP7777988B2 JP7777988B2 (ja) 2025-12-01

Family

ID=74101301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578065A Active JP7777988B2 (ja) 2019-07-03 2020-07-03 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
JP2025197401A Pending JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025197401A Pending JP2026032063A (ja) 2019-07-03 2025-11-18 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Country Status (9)

Country Link
US (1) US20220356457A1 (https=)
EP (1) EP3994275A4 (https=)
JP (2) JP7777988B2 (https=)
KR (1) KR20220032576A (https=)
CN (1) CN114258431A (https=)
AU (1) AU2020301037A1 (https=)
BR (1) BR112021026789A2 (https=)
CA (1) CA3145676A1 (https=)
WO (1) WO2021003469A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102914621B1 (ko) 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
BR112021026852A2 (pt) * 2019-07-03 2022-02-22 Palleon Pharmaceuticals Inc Sialidases recombinantes e métodos de uso das mesmas
US20220387616A1 (en) * 2019-07-03 2022-12-08 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
JP7777988B2 (ja) * 2019-07-03 2025-12-01 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
WO2025217138A1 (en) * 2024-04-09 2025-10-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
WO2026037175A1 (zh) 2024-08-16 2026-02-19 上海宝济药业股份有限公司 靶向靶细胞的复合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE474925T1 (de) * 1993-05-17 2010-08-15 Genentech Inc Rekombinante cho zell sialidase
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2007108464A1 (ja) * 2006-03-20 2007-09-27 Kyowa Hakko Kogyo Co., Ltd. 哺乳動物由来細胞質シアリダーゼに対する抗体
CN100376689C (zh) * 2006-03-28 2008-03-26 北京大学 一种预测达菲类药物用药安全性的方法
CN101896616B (zh) * 2007-10-12 2014-06-04 西格马-奥利奇股份有限公司 提高糖蛋白唾液酸化作用的组合物与方法
AU2010270979B2 (en) * 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物
US10081801B2 (en) * 2013-04-12 2018-09-25 Danmarks Tekniske Universitet Mutant sialidase having trans-sialidase activity for use in production of sialylated glycans
WO2018006066A1 (en) * 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
MX2018016393A (es) * 2016-07-01 2019-08-12 Univ Leland Stanford Junior Conjugados para la edición de la superficie de la celula diana.
DK3630968T3 (da) * 2017-05-26 2024-07-29 Genovis Ab Enzymer til glycananalyse
KR102914621B1 (ko) * 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells
JP7777988B2 (ja) * 2019-07-03 2025-12-01 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法

Similar Documents

Publication Publication Date Title
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
US20240059751A1 (en) Interleukin-2 variants and methods of uses thereof
US20210122805A1 (en) Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
AU2010246108B2 (en) FGF21 mutants and uses thereof
AU2009256232B2 (en) FGF21 mutants and uses thereof
JP2021020905A5 (https=)
US12497462B2 (en) Anti-CD26 proteins and uses thereof
JP2007505643A5 (https=)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2017527272A5 (https=)
JPWO2021189139A5 (https=)
JPWO2019140050A5 (https=)
JP2024517871A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
CN104292331B (zh) 人源抗人α干扰素抗体及其应用
JPWO2021003469A5 (https=)
JPWO2019121906A5 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
JPWO2022006492A5 (https=)
KR102334315B1 (ko) 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
CA3218571A1 (en) Methods of screening and expression of disulfide-bonded binding polypeptides
JPWO2022150516A5 (https=)
US20250109207A1 (en) Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof
JPWO2022150521A5 (https=)
Lyczak et al. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein
JPWO2022150507A5 (https=)
JPWO2022020353A5 (https=)